These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35518522)

  • 21. Safety and Efficacy of Combination Therapy of Remdesivir, Baricitinib, and High-dose Steroids in Patients Hospitalized with Moderate to Severe COVID-19.
    Nagasawa R; Niwa T; Hagiwara E; Oda T; Yamada S; Okuda R; Baba T; Komatsu S; Kaneko T; Ogura T
    Intern Med; 2023 Nov; 62(21):3125-3130. PubMed ID: 37438142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19-Associated Pulmonary Aspergillosis (CAPA).
    Dimopoulos G; Almyroudi MP; Myrianthefs P; Rello J
    J Intensive Med; 2021 Oct; 1(2):71-80. PubMed ID: 36785564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Covid-19 associated pulmonary aspergillosis with extensive cavitary pneumonia: A case report.
    Hanif S; Iqbal M; Sethi SM
    J Pak Med Assoc; 2023 Jan; 73(1):174-176. PubMed ID: 36842034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.
    Verweij PE; Brüggemann RJM; Azoulay E; Bassetti M; Blot S; Buil JB; Calandra T; Chiller T; Clancy CJ; Cornely OA; Depuydt P; Koehler P; Lagrou K; de Lange D; Lass-Flörl C; Lewis RE; Lortholary O; Liu PL; Maertens J; Nguyen MH; Patterson TF; Rijnders BJA; Rodriguez A; Rogers TR; Schouten JA; Wauters J; van de Veerdonk FL; Martin-Loeches I
    Intensive Care Med; 2021 Aug; 47(8):819-834. PubMed ID: 34160631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mortality comparision in patients receiving either Remdesivir or Remdesivir plus Baricitinib combination in case of moderate to severe COVID-19 Pneumonia: A retrospective study.
    Das D; Mukhopadhyay P; Banerjee D
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Dexamethasone on the Incidence and Outcome of COVID-19 Associated Pulmonary Aspergillosis (CAPA) in Critically Ill Patients during First- and Second Pandemic Wave-A Single Center Experience.
    Dubler S; Turan ÖC; Schmidt KD; Rath PM; Verhasselt HL; Maier S; Skarabis A; Brenner T; Herbstreit F
    Diagnostics (Basel); 2022 Dec; 12(12):. PubMed ID: 36553055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19.
    Thoms BL; Gosselin J; Libman B; Littenberg B; Budd RC
    SN Compr Clin Med; 2022; 4(1):42. PubMed ID: 35079694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
    Kojima Y; Nakakubo S; Kamada K; Yamashita Y; Takei N; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
    J Med Virol; 2022 Dec; 94(12):5702-5712. PubMed ID: 35916111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corticosteroids as risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients.
    Leistner R; Schroeter L; Adam T; Poddubnyy D; Stegemann M; Siegmund B; Maechler F; Geffers C; Schwab F; Gastmeier P; Treskatsch S; Angermair S; Schneider T
    Crit Care; 2022 Jan; 26(1):30. PubMed ID: 35090528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 Associated Pulmonary Aspergillosis: A Case Series.
    Yulianti M; Johan C; Tenda ED; Singh G; Herikurniawan H; Wijaya IPEK
    Acta Med Indones; 2022 Apr; 54(2):292-298. PubMed ID: 35818652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors for poor outcomes in patients with severe COVID-19 treated with remdesivir plus dexamethasone in Taiwan.
    Lai YH; Lee YC; Chen IR; Lin SN; Chang YL; Lu CC; Wu PF; Lin YT
    J Microbiol Immunol Infect; 2023 Dec; 56(6):1207-1213. PubMed ID: 37696685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study.
    Hatzl S; Reisinger AC; Posch F; Prattes J; Stradner M; Pilz S; Eller P; Schoerghuber M; Toller W; Gorkiewicz G; Metnitz P; Rief M; Prüller F; Rosenkranz AR; Valentin T; Krause R; Hoenigl M; Schilcher G
    Crit Care; 2021 Sep; 25(1):335. PubMed ID: 34526087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study.
    Marrone A; Nevola R; Sellitto A; Cozzolino D; Romano C; Cuomo G; Aprea C; Schwartzbaum MXP; Ricozzi C; Imbriani S; Rinaldi L; Gjeloshi K; Padula A; Ranieri R; Ruosi C; Meo LA; Abitabile M; Cinone F; Carusone C; Adinolfi LE
    Clin Infect Dis; 2022 Aug; 75(1):e403-e409. PubMed ID: 35084022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis (CAPA): a systematic review and meta-analysis.
    Chong WH; Saha BK; Neu KP
    Infection; 2022 Feb; 50(1):43-56. PubMed ID: 34570355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic and Phenotypic Analysis of COVID-19-Associated Pulmonary Aspergillosis Isolates of Aspergillus fumigatus.
    Steenwyk JL; Mead ME; de Castro PA; Valero C; Damasio A; Dos Santos RAC; Labella AL; Li Y; Knowles SL; Raja HA; Oberlies NH; Zhou X; Cornely OA; Fuchs F; Koehler P; Goldman GH; Rokas A
    Microbiol Spectr; 2021 Sep; 9(1):e0001021. PubMed ID: 34106569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transient Leukopenia Induced by Combination Therapy for Severe SARS-CoV-2 Pneumonia.
    Sullivan S; Leelaviwat N; Davalos J; Evans A; Abdelnabi M; Mittal N
    Eur J Case Rep Intern Med; 2022; 9(10):003636. PubMed ID: 36415839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A fatal case of COVID-19-associated invasive pulmonary aspergillosis.
    Iwanaga Y; Kawanami T; Yamasaki K; Sakakibara H; Ikushima I; Ikegami H; Tahara M; Akata K; Mukae H; Yatera K
    J Infect Chemother; 2021 Jul; 27(7):1102-1107. PubMed ID: 33867266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics.
    Chatterjee B; Thakur SS
    Front Immunol; 2022; 13():830990. PubMed ID: 35634324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Combination Therapy With The JAK Inhibitor Baricitinib In The Treatment of COVID-19.
    Thoms BL; Gosselin J; Libman B; Littenberg B; Budd R
    Res Sq; 2021 Sep; ():. PubMed ID: 34518834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review.
    Chong WH; Neu KP
    J Hosp Infect; 2021 Jul; 113():115-129. PubMed ID: 33891985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.